Fig 2: Pathological scores of ADAM8, ADAM9, ADAM10, ADAM12 and ADAM17 expression according to the staining intensity and the percentage of cell staining. (A) Pathological scores of ADAMs in adjacent non-cancerous gastric tissues (n=15) and gastric cancer tissues (n=15). (B) Pathological scores of ADAMs in positive metastatic lymph node and negative metastatic lymph node tissues (n=15). *P<0.05, **P<0.01 vs. the corresponding control group. ADAM, disintegrin and metalloproteinase domain-containing protein.